HRP20230585T1 - Novi derivati amino pirimidina - Google Patents

Novi derivati amino pirimidina Download PDF

Info

Publication number
HRP20230585T1
HRP20230585T1 HRP20230585TT HRP20230585T HRP20230585T1 HR P20230585 T1 HRP20230585 T1 HR P20230585T1 HR P20230585T T HRP20230585T T HR P20230585TT HR P20230585 T HRP20230585 T HR P20230585T HR P20230585 T1 HRP20230585 T1 HR P20230585T1
Authority
HR
Croatia
Prior art keywords
alkyl
optionally substituted
halogen
hydrogen
cyclopropyl
Prior art date
Application number
HRP20230585TT
Other languages
English (en)
Croatian (hr)
Inventor
Daniela Angst
Francois Gessier
Anna Vulpetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20230585T1 publication Critical patent/HRP20230585T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
HRP20230585TT 2013-11-29 2014-11-28 Novi derivati amino pirimidina HRP20230585T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29
EP20158961.1A EP3689865B1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives

Publications (1)

Publication Number Publication Date
HRP20230585T1 true HRP20230585T1 (hr) 2023-09-01

Family

ID=49674216

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20230585TT HRP20230585T1 (hr) 2013-11-29 2014-11-28 Novi derivati amino pirimidina
HRP20171999TT HRP20171999T1 (hr) 2013-11-29 2014-11-28 Novi derivati aminopirimidina
HRP20200775TT HRP20200775T1 (hr) 2013-11-29 2020-05-12 Novi derivati amino-pirimidina

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20171999TT HRP20171999T1 (hr) 2013-11-29 2014-11-28 Novi derivati aminopirimidina
HRP20200775TT HRP20200775T1 (hr) 2013-11-29 2020-05-12 Novi derivati amino-pirimidina

Country Status (42)

Country Link
US (6) US9512084B2 (OSRAM)
EP (5) EP3689865B1 (OSRAM)
JP (2) JP6342495B2 (OSRAM)
KR (2) KR102421388B1 (OSRAM)
CN (2) CN110172056B (OSRAM)
AP (1) AP2016009158A0 (OSRAM)
AR (1) AR098549A1 (OSRAM)
AU (1) AU2014356069B2 (OSRAM)
BR (1) BR112016010397B1 (OSRAM)
CA (1) CA2926908C (OSRAM)
CL (1) CL2016001055A1 (OSRAM)
CR (1) CR20160244A (OSRAM)
CU (1) CU24384B1 (OSRAM)
CY (3) CY1119705T1 (OSRAM)
DK (3) DK3299368T3 (OSRAM)
EA (1) EA031218B1 (OSRAM)
EC (1) ECSP16054826A (OSRAM)
ES (4) ES3040769T3 (OSRAM)
FI (1) FI3689865T3 (OSRAM)
HR (3) HRP20230585T1 (OSRAM)
HU (3) HUE037588T2 (OSRAM)
IL (1) IL244943B (OSRAM)
JO (1) JO3314B1 (OSRAM)
LT (3) LT3299368T (OSRAM)
MA (1) MA39055B1 (OSRAM)
MX (1) MX367911B (OSRAM)
MY (2) MY179059A (OSRAM)
NO (1) NO3074386T3 (OSRAM)
NZ (1) NZ718835A (OSRAM)
PE (1) PE20160869A1 (OSRAM)
PH (1) PH12016500791A1 (OSRAM)
PL (3) PL3299368T3 (OSRAM)
PT (3) PT3074386T (OSRAM)
RS (3) RS64275B1 (OSRAM)
SI (3) SI3299368T1 (OSRAM)
SV (1) SV2016005206A (OSRAM)
TN (1) TN2016000128A1 (OSRAM)
TW (1) TWI652261B (OSRAM)
UA (1) UA117256C2 (OSRAM)
UY (1) UY35858A (OSRAM)
WO (1) WO2015079417A1 (OSRAM)
ZA (1) ZA201602275B (OSRAM)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
PL3888674T3 (pl) 2014-04-07 2024-09-23 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3722316A1 (en) 2014-07-21 2020-10-14 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
US10851149B2 (en) 2014-08-14 2020-12-01 The Trustees Of The University Of Pennsylvania Treatment of cancer using GFR α-4 chimeric antigen receptor
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114107424A (zh) 2014-10-08 2022-03-01 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
WO2016164580A1 (en) * 2015-04-07 2016-10-13 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP3393504B1 (en) 2015-12-22 2025-09-24 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CN116769050A (zh) 2016-07-20 2023-09-19 犹他大学研究基金会 Cd229 car t细胞及其使用方法
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
MA46963A (fr) 2016-12-03 2019-10-09 Juno Therapeutics Inc Méthodes pour déterminer le dosage de céllules car-t
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018223101A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
CA3067602A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
TWI694995B (zh) * 2017-11-06 2020-06-01 美商美國禮來大藥廠 Btk抑制劑化合物
EP3716980A1 (en) 2017-12-01 2020-10-07 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
CN112204048A (zh) 2017-12-15 2021-01-08 朱诺治疗学股份有限公司 抗cct5结合分子及其使用方法
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
TWI890660B (zh) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
JP7555327B2 (ja) 2018-07-25 2024-09-24 ノバルティス アーゲー Ｎｌｒｐ３インフラマソーム阻害剤
IL312413B1 (en) 2018-08-29 2025-09-01 Acerta Pharma Bv Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-enol)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
CA3117419A1 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
PE20211058A1 (es) 2018-11-01 2021-06-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
KR20210104713A (ko) 2018-11-16 2021-08-25 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법
WO2020113194A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
WO2020160050A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2020234780A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
CN113840821A (zh) * 2019-05-23 2021-12-24 诺华股份有限公司 Btk抑制剂的晶型
CN113795255A (zh) 2019-05-23 2021-12-14 诺华股份有限公司 使用布鲁顿酪氨酸激酶抑制剂治疗慢性自发性荨麻疹的方法
FI3972603T3 (fi) * 2019-05-23 2024-12-04 Novartis Ag Menetelmiä sjögrenin oireyhtymän hoitamiseksi käyttäen brutonin tyrosiinikinaasin estäjää
EP4081514A1 (en) * 2019-12-23 2022-11-02 Biogen MA Inc. Btk inhibitors
WO2021207689A2 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
CN116209444A (zh) * 2020-08-14 2023-06-02 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
EP4196478A1 (en) 2020-08-14 2023-06-21 Novartis AG Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
KR20230134560A (ko) 2021-01-26 2023-09-21 노파르티스 아게 약학적 조성물
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
KR20240055038A (ko) * 2021-09-03 2024-04-26 노파르티스 아게 다발성 경화증 치료를 위한 lou064
MX2024007354A (es) 2021-12-14 2024-06-28 Novartis Ag Metodos de tratamiento usando lou064.
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
KR20250029137A (ko) 2022-06-22 2025-03-04 주노 쎄러퓨티크스 인코퍼레이티드 Cd19-표적화된 car t 세포의 2차 요법을 위한 치료 방법
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
TW202415644A (zh) 2022-09-30 2024-04-16 瑞士商諾華公司 合成方法及中間體
AR131320A1 (es) 2022-12-13 2025-03-05 Juno Therapeutics Inc Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
TW202515850A (zh) * 2023-09-22 2025-04-16 大陸商江蘇恆瑞醫藥股份有限公司 雜芳基類化合物、其製備方法及其在醫藥上的應用
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法
US20250243170A1 (en) 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity
US20250304538A1 (en) 2024-04-02 2025-10-02 Novartis Ag Process of preparing remibrutinib substantially free of nitrosamine impurity

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
US20030040461A1 (en) 2000-10-23 2003-02-27 Mcatee C. Patrick Modulators of Bruton'sTyrosine Kinase and Bruton's Tyrosine Kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related diseases states
RU2329263C2 (ru) 2000-11-07 2008-07-20 Новартис Аг Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
EP1576137A4 (en) 2002-10-29 2010-06-30 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
AU2003297740B2 (en) 2002-12-09 2008-09-11 The Board Of Regents Of The University Of Texas System Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3)
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
TW200505442A (en) 2003-05-19 2005-02-16 Genomics Inst Of The Novartis Res Foundation Immunosuppressant compounds and compositions
ES2389203T3 (es) 2004-01-12 2012-10-24 Ym Biosciences Australia Pty Ltd Inhibidores de quinasa selectivos
TW200716551A (en) 2005-03-10 2007-05-01 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
CA2680589A1 (en) 2007-03-14 2008-09-18 Universita' Degli Studi Di Milano - Bicocca Modulator compounds of the drug resistance in epithelial tumour cells
JP5529852B2 (ja) 2008-05-06 2014-06-25 ジリード コネティカット，インコーポレイティド 置換アミド、その製造法及びＢｔｋインヒビターとしての使用
PT2300459E (pt) 2008-07-02 2013-07-04 Hoffmann La Roche Novas fenilpirazinonas utilizadas como inibidores de cinase
EP3311818A3 (en) 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
SG175287A1 (en) 2009-04-24 2011-11-28 Hoffmann La Roche Inhibitors of bruton's tyrosine kinase
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
UY33245A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
WO2012135801A1 (en) 2011-04-01 2012-10-04 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
CA2836449C (en) 2011-05-17 2021-04-27 The Regents Of The University Of California Kinase inhibitors
LT2718270T (lt) 2011-06-10 2022-08-10 Merck Patent Gmbh Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai
EP2726077A4 (en) 2011-06-28 2014-12-10 Pharmacyclics Inc METHODS AND COMPOSITIONS FOR INHIBITING BONE RESORPTION
BR112014000314A2 (pt) 2011-07-08 2017-01-10 Novartis Ag derivados de pirrolo pirimidina
WO2013023084A2 (en) 2011-08-09 2013-02-14 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
CN110801454A (zh) 2011-10-19 2020-02-18 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的用途
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
CA2854603A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
EP2824099A4 (en) 2012-03-09 2015-11-11 Carna Biosciences Inc NOVEL TRIAZINE DERIVATIVE
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
AU2013250726B2 (en) 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
US9133134B2 (en) 2012-05-16 2015-09-15 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
MX2015001802A (es) 2012-08-10 2015-05-07 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk.
KR102194611B1 (ko) 2012-10-04 2020-12-23 유니버시티 오브 유타 리서치 파운데이션 티로신 수용체 키나아제 btk 억제제로서 치환된 n-(3-(피리미딘-4-일)페닐)아크릴아미드 유사체
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
EP4606377A3 (en) 2025-11-26
CL2016001055A1 (es) 2016-10-28
BR112016010397A8 (pt) 2020-04-22
PL3074386T3 (pl) 2018-03-30
TWI652261B (zh) 2019-03-01
PL3689865T3 (pl) 2023-07-31
EP3299368B1 (en) 2020-02-26
EP3689865A1 (en) 2020-08-05
JO3314B1 (ar) 2019-03-13
PH12016500791B1 (en) 2016-06-13
AR098549A1 (es) 2016-06-01
AU2014356069A1 (en) 2016-05-05
CA2926908C (en) 2021-10-26
CN110172056A (zh) 2019-08-27
SI3689865T1 (sl) 2023-07-31
SI3299368T1 (sl) 2020-07-31
EP3074386A1 (en) 2016-10-05
EA201691125A1 (ru) 2016-09-30
HUE049794T2 (hu) 2020-10-28
RS60251B1 (sr) 2020-06-30
IL244943B (en) 2020-04-30
DK3689865T3 (en) 2023-06-19
US9512084B2 (en) 2016-12-06
UY35858A (es) 2015-06-30
EP3299368A1 (en) 2018-03-28
EP4219478B1 (en) 2025-06-11
MX367911B (es) 2019-09-11
US11673868B2 (en) 2023-06-13
FI3689865T3 (fi) 2023-06-12
LT3689865T (lt) 2023-07-10
LT3074386T (lt) 2017-12-27
CY1126056T1 (el) 2023-11-15
US20230312483A1 (en) 2023-10-05
DK3074386T3 (en) 2018-01-22
KR20220044370A (ko) 2022-04-07
SV2016005206A (es) 2016-11-21
LT3299368T (lt) 2020-05-25
RS56657B1 (sr) 2018-03-30
TW201609666A (zh) 2016-03-16
AU2014356069B2 (en) 2017-06-15
MY191381A (en) 2022-06-22
PL3299368T3 (pl) 2020-08-10
CN105683181A (zh) 2016-06-15
JP2016538313A (ja) 2016-12-08
ES2947770T3 (es) 2023-08-18
US20200010426A1 (en) 2020-01-09
EP3689865B1 (en) 2023-03-29
PE20160869A1 (es) 2016-09-08
KR102421388B1 (ko) 2022-07-18
CY1119705T1 (el) 2018-06-27
CU20160078A7 (es) 2016-09-30
JP6342495B2 (ja) 2018-06-13
CN110172056B (zh) 2022-04-19
TN2016000128A1 (en) 2017-10-06
NZ718835A (en) 2021-12-24
US20150152068A1 (en) 2015-06-04
US10457647B2 (en) 2019-10-29
ES2791525T3 (es) 2020-11-04
US20160235746A1 (en) 2016-08-18
HUE062248T2 (hu) 2023-10-28
EA031218B1 (ru) 2018-12-28
CA2926908A1 (en) 2015-06-04
EP3074386B1 (en) 2017-10-11
DK3299368T3 (da) 2020-05-25
HRP20171999T1 (hr) 2018-02-09
JP6667573B2 (ja) 2020-03-18
MA39055A1 (fr) 2018-02-28
PT3299368T (pt) 2020-05-28
ES2655527T3 (es) 2018-02-20
RS64275B1 (sr) 2023-07-31
NO3074386T3 (OSRAM) 2018-03-10
ES3040769T3 (en) 2025-11-04
HK1252317A1 (en) 2019-05-24
HUE037588T2 (hu) 2018-09-28
PT3689865T (pt) 2023-06-16
KR102380539B1 (ko) 2022-03-29
US11180460B2 (en) 2021-11-23
MY179059A (en) 2020-10-26
WO2015079417A1 (en) 2015-06-04
BR112016010397B1 (pt) 2023-04-11
CU24384B1 (es) 2019-03-04
CY1122924T1 (el) 2021-10-29
PH12016500791A1 (en) 2016-06-13
EP4219478A1 (en) 2023-08-02
PT3074386T (pt) 2017-11-15
EP4606377A2 (en) 2025-08-27
MA39055B1 (fr) 2018-10-31
CR20160244A (es) 2016-07-29
HK1223368A1 (en) 2017-07-28
CN105683181B (zh) 2019-04-23
US20180251432A1 (en) 2018-09-06
SI3074386T1 (en) 2018-02-28
HRP20200775T1 (hr) 2020-07-24
MX2016006908A (es) 2016-08-17
US20220041561A1 (en) 2022-02-10
UA117256C2 (uk) 2018-07-10
KR20160088877A (ko) 2016-07-26
AP2016009158A0 (en) 2016-04-30
IL244943A0 (en) 2016-05-31
JP2018141005A (ja) 2018-09-13
ECSP16054826A (es) 2017-10-31
ZA201602275B (en) 2017-08-30

Similar Documents

Publication Publication Date Title
HRP20230585T1 (hr) Novi derivati amino pirimidina
HRP20211583T1 (hr) Tienopiridini i benzotiofeni korisni kao irak4 inhibitori
JP2014520793A5 (OSRAM)
HRP20191579T1 (hr) Spojevi kao modulatori za ror gama
HRP20171030T1 (hr) Modulatori enzima koji modificiraju metil, njihove smjese i uporaba
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
HRP20210472T1 (hr) Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4
PE20121327A1 (es) Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello
SI3008053T1 (en) PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS
PH12016502523A1 (en) Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
HRP20221043T1 (hr) Derivat oksi-fluoropiperidina kao inhibitor kinaze
JP2016516724A5 (OSRAM)
NZ595989A (en) Heteroaryl compounds and uses thereof
HRP20180411T1 (hr) Predlijekovi inhibitora aminokinazolinske kinaze
JP2017530185A5 (OSRAM)
JP2020524687A5 (OSRAM)
PE20140226A1 (es) Compuestos de triazolopiridina
AR081197A1 (es) Lactamas sustituidas con piperidinil o como moduladores de gpr 119
JP2014516074A5 (OSRAM)
HRP20201158T1 (hr) Derivati indolin-2-ona
HRP20120762T1 (hr) Tetrasupstituirani piridazini kao inhibitori hedgehog puta
HRP20171031T1 (hr) Supstituirani tetrahidrokarbazol i karbazol karboksamid spojevi koji se koriste kao inhibitori kinaze
AR082827A1 (es) Compuestos de aril-metiloxi-benzamida, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento util para el tratamiento o la profilaxis de la enfermedad de parkinson
HRP20180973T1 (hr) Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora
PH12014501415A1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists